Metabolic modes of action of the statins in the hyperlipoproteinemias

被引:52
作者
Aguilar-Salinas, CA
Barrett, H
Schonfeld, G [1 ]
机构
[1] Washington Univ, Sch Med, St Louis, MO 63130 USA
[2] Univ Washington, SAAM Inst, Seattle, WA 98195 USA
[3] Inst Nacl Nutr, Dept Diabet & Metab Lipidos, Mexico City, DF, Mexico
关键词
physiologic modes of action; statins; inhibitors;
D O I
10.1016/S0021-9150(98)00198-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Conflicting results have been published during the past few years regarding the physiologic modes of action of the hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitors, generally referred to as statins, using standard doses. Three mechanisms have been described: increased LDL catabolic rate, increased removal of LDL precursors resulting in decreased LDL production and decreased VLDL production. The physiologic effects of statins seem to depend on the underlying pathology of the disorders under therapy. More recent data using either the more potent atorvastatin or larger doses of previously available statins (e.g. simvastatin 80-160 mg/day), suggest that both the potency of the statins and the underlying pathopysiology are important in determining the predominant physiologic responses of patients. To understand physiologic responses more completely, drug-dose-physiologic response curves of apo B kinetics in various groups of patients are needed. Simultaneous studies of apo B, triglycerides and cholesterol metabolism are also needed and are currently feasible. (C) 1998 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:203 / 207
页数:5
相关论文
共 47 条
[1]  
AGUILAR CA, 1995, ARTERIOSCLER THROMB, V15, P40
[2]   A familial combined hyperlipidemic kindred with impaired apolipoprotein B catabolism - Kinetics of apolipoprotein B during placebo and pravastatin therapy [J].
AguilarSalinas, CA ;
Barrett, PHR ;
Pulai, J ;
Zhu, XL ;
Schonfeld, G .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1997, 17 (01) :72-82
[3]  
AGUILARSALINAS CA, 1995, J LIPID RES, V36, P188
[4]   EFFECTS OF LOVASTATIN THERAPY ON VERY-LOW-DENSITY LIPOPROTEIN TRIGLYCERIDE-METABOLISM IN SUBJECTS WITH COMBINED HYPERLIPIDEMIA - EVIDENCE FOR REDUCED ASSEMBLY AND SECRETION OF TRIGLYCERIDE-RICH LIPOPROTEINS [J].
ARAD, Y ;
RAMAKRISHNAN, R ;
GINSBERG, HN .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1992, 41 (05) :487-493
[5]  
ARAD Y, 1990, J LIPID RES, V31, P567
[6]   Design and analysis of lipid tracer kinetic studies [J].
Barrett, PHR ;
Foster, DM .
CURRENT OPINION IN LIPIDOLOGY, 1996, 7 (03) :143-148
[7]   ApoB-100 secretion by HepG2 cells is regulated by the rate of triglyceride biosynthesis but not by intracellular lipid pools [J].
Benoist, F ;
GrandPerret, T .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1996, 16 (10) :1229-1235
[8]   MEVINOLIN AND COLESTIPOL STIMULATE RECEPTOR-MEDIATED CLEARANCE OF LOW-DENSITY LIPOPROTEIN FROM PLASMA IN FAMILIAL HYPERCHOLESTEROLEMIA HETEROZYGOTES [J].
BILHEIMER, DW ;
GRUNDY, SM ;
BROWN, MS ;
GOLDSTEIN, JL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1983, 80 (13) :4124-4128
[9]   REGULATION OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE-ACTIVITY IN HUMAN FIBROBLASTS BY LIPOPROTEINS [J].
BROWN, MS ;
DANA, SE ;
GOLDSTEIN, JL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1973, 70 (07) :2162-2166
[10]  
BROWN MS, 1978, J BIOL CHEM, V253, P1121